Induction and high dose of cytarabine in consolidation. Medical search. Frequent questions

The traditional regimen for induction chemotherapy, irrespective of favorable intermediate or unfavorable-risk AML, is the 7+3 regimen. (pharmacytimes.com)
A FAB/LMB96 group C chemotherapy regimen for aggressive and high-risk cancer was administered with a marked improvement in clinical symptoms. (hindawi.com)
Modern induction chemotherapy produces 60% to 80% complete remissions in adults with newly diagnosed acute myelogenous leukemia. (elsevierpure.com)
We analyzed the long-term results of high-dose cytarabine-anthracycline consolidation chemotherapy without maintenance treatment and examined the effect of major prognostic factors, including age, sex, history of preleukemia, and cytogenetics. (elsevierpure.com)
Toxicity of consolidation chemotherapy included treatment-related death in nine patients and serious neurotoxicity in five. (elsevierpure.com)
EA9181, A Phase III Randomized Trial of Steroids+Tyrosine Kinase Inhibitor Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Rochester, Minn. This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. (mayo.edu)
For the study, patients were given either midostaurin or placebo in addition to standard daunorubicin/cytarabine chemotherapy during the induction stage. (incitasecurity.com)
Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy. (ashpublications.org)
Treatment includes induction chemotherapy to achieve remission and postremission chemotherapy (with or without stem cell transplantation) to avoid relapse. (msdmanuals.com)
Efforts to overcome chemotherapy resistance by including multidrug resistance modifiers (e.g., cyclosporin or its analogue PSC 833) in the induction schedule have as yet not met with reproducible success in prospective comparative studies. (ashpublications.org)
High-dose chemotherapy and autologous stem cell transplantation (HCT-ASCT) after high-dose methotrexate (MTX)-based immuno-chemotherapy has become an increasingly used treatment approach in eligible elderly PCNSL patients with promising feasibility and efficacy, but has not been compared with conventional chemotherapy approaches. (biomedcentral.com)
Doctors may use a combination of chemotherapy drugs, such as cytarabine, and an anthracycline drug, such as daunorubicin. (medicalnewstoday.com)
This phase involves providing a person with low doses of chemotherapy or other drugs for months to years. (medicalnewstoday.com)
Doctors can use stem cell transplants or bone marrow transplants to give people with AML higher doses of chemotherapy. (medicalnewstoday.com)
Doctors may also recommend this treatment to those with relapsed or resistant AML after they undergo re-induction chemotherapy. (medicalnewstoday.com)
For consolidation chemotherapy or for the management of toxic effects of chemotherapy, readmission is required. (medscape.com)
The drug is approved for use in combination with standard Daunorubicin and Cytarabine induction & high- dose Cytarabine consolidation chemotherapy, and for patients in complete response followed by Midostaurin single-agent maintenance therapy for adults with newly diagnosed Acute Myeloid Leukemia (AML) who are FLT3 mutation-positive. (gubbanews.com)
The Food and Drug Administration approved quizartinib (Vanflyta, Daiichi Sankyo, Inc.) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (cancerfax.com)
1 , 2 The current standard of care consists of induction therapy using high-dose methotrexate-based chemotherapy, followed by consolidation therapy with either whole-brain radiotherapy (WBRT) or autologous hematopoietic cell transplant (AHCT). (jamanetwork.com)
In response to restrictions brought on by the COVID-19 pandemic, our institution adopted triple intrathecal (IT) chemotherapy for CNS prophylaxis during HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine). (bvsalud.org)
The chemotherapy regimen known as FLAG-GO (fludarabine, cytarabine, granulocyte colony-stimulating factor, and gemtuzumab ozogamicin) is used at The University of Texas MD Anderson Cancer Center, Houston, and other centers for induction treatment in favorable-risk AML. (ascopost.com)
Incorporating gemtuzumab ozogamicin into induction chemotherapy with FLAG (FLAG-GO) achieves similar survival to FLAG plus idarubicin in favorable-risk AML. (ascopost.com)
Additional treatment with chemotherapy is rarely curative and some patients will choose a palliative approach where drugs are administered in non-toxic doses to keep the disease under control for as long as possible. (radiationoncologyassociates.co)
An allogeneic stem cell transplant is a procedure that is performed to repair the damage caused by high-dose chemotherapy. (radiationoncologyassociates.co)
High-dose chemotherapy (HDC) kills more cancer cells than lower-dose conventional chemotherapy. (radiationoncologyassociates.co)
Chemotherapy for AML is broken down into three phases: induction phase, consolidation (or intensification), and maintenance phase. (oncolink.org)
Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells. (uchicagomedicine.org)

Standard dosage of cytarabine is given on a consistent basis for 7 days and then an anthracycline drug, such as daunorubicin or idarubicin, is administered for 3 days. (pharmacytimes.com)
3. As is usual with antileukemic agents, severe myelosuppression occurs when idarubicin hydrochloride is used at effective therapeutic doses. (nih.gov)
Pharmacokinetic studies have been performed in adult leukemia patients with normal renal and hepatic function following intravenous administration of 10 to 12 mg/m 2 of idarubicin daily for 3 to 4 days as a single agent or combined with cytarabine. (nih.gov)
The elimination rate of idarubicin from plasma is slow with an estimated mean terminal half-life of 22 hours (range, 4 to 48 hours) when used as a single agent and 20 hours (range, 7 to 38 hours) when used in combination with cytarabine. (nih.gov)
Since the introduction of the anthracyclines (daunorubicin, idarubicin) and cytarabine, these therapeutic agents have been the cornerstones of remission induction therapy for adult AML. (ashpublications.org)
The treatment plan included the combination of a single high-dose idarubicin and high-dose cytarabine as induction therapy followed by an intensive consolidation and stem cell transplant (SCT). (unipv.it)
Alternatively, high-dose cytarabine combined with idarubicin, daunorubicin, or mitoxantrone can be used as induction therapy in younger patients. (medscape.com)
Induction included ATRA and idarubicin. (targetedonc.com)
Therefore, this trial evaluates the safety and efficacy of fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin, combined with the B-cell lymphoma-2 inhibitor venetoclax in newly diagnosed AML (ND-AML) and relapsed/refractory AML (R/R-AML). (bjh.be)
idarubicin was permitted (days 3-4) in up to two consolidation cycles at the discretion of the treating physician. (bjh.be)
Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin plus venetoclax represents an effective intensive treatment regimen in ND-AML and R/R-AML patients, associated with deep remissions and a high rate of transition to successful transplantation. (bjh.be)
Induction and consolidation therapy comprising venetoclax plus fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) was highly effective for the treatment of newly diagnosed AML, according to research. (devbrandcast.com)

The absence of a methoxy group at position 4 of the anthracycline structure gives the compound a high lipophilicity which results in an increased rate of cellular uptake compared with other anthracyclines. (nih.gov)
Anthracycline dose intensification in acute myeloid leukemia. (qxmd.com)
In young adults with acute myeloid leukemia (AML), intensification of the anthracycline dose during induction therapy has improved the rate of complete remission but not of overall survival. (qxmd.com)
According to results from a trial conducted by investigators from the Children’s Oncology Group, treatment with arsenic trioxide consolidation was effective and safe in newly diagnosed pediatric patients with acute promyelocytic leukemia, allowing a significant reduction in cumulative anthracycline doses. (targetedonc.com)
ldquo;The use of ATO allowed an approximate 40% decrease in cumulative anthracycline dosing without compromising survival in standard-risk APL compared with a benchmark from the AIDA 0493 trial. (targetedonc.com)
Standard-risk patients received 2 additional consolidation courses that included high-dose cytarabine and anthracycline, and maintenance therapy comprising ATRA, oral methotrexate, and mercaptopurine. (targetedonc.com)

It was only after the introduction of daunorubicin and cytarabine that complete remissions and long-term success were achieved (Crowther D et al 1970).The prognosis of AML has improved steadily since the 1970s. (altmeyers.org)

75 years old) followed by cytarabine consolidations and/or allogeneic stem-cell transplantation (ASCT). (dovepress.com)
No consolidation with autologous or allogeneic stem cell transplantation was performed. (ashpublications.org)
Patients who had a complete remission were offered either allogeneic hematopoietic stem-cell transplantation or high-dose cytarabine, with or without a single dose of the monoclonal antibody gemtuzumab ozogamicin, followed by autologous stem-cell transplantation. (qxmd.com)
Recent study results demonstrated that FLAG-IDA plus venetoclax represents an effective intensive induction regimen for ND-AML and relapsed/refractory AML (R/R-AML), with particular utility as a bridge to allogeneic stem cell transplantation in the R/R-AML population. (bjh.be)

citation needed] "Nordic Protocol (Maxi-CHOP and High Dose Cytarabine) for Mantle Cell Lymphoma (MCL)" (PDF). (wikipedia.org)
Venetoclax is active in other lymphoid malignancies including several B cell non-Hodgkin lymphomas, acute lymphoblastic leukemia and multiple myeloma, with the highest intrinsic sensitivity observed in mantle cell lymphoma and Waldenstrom macroglobulinemia. (biomedcentral.com)

Various acceptable induction regimens are available. (medscape.com)
[ 35 ] These induction regimens were administered with cytarabine 100 mg/m 2 /d for 7 days for the first cycle. (medscape.com)
With considerable advances in therapy, including the introduction of ATRA initially as a single agent and then in combination with anthracyclines, and more recently by development of arsenic trioxide (ATO)-containing regimens, APL is now characterized by complete remission rates of 90% and cure rates of ∼ 80%, even higher among low-risk patients. (nature.com)
Gemtuzumab ozogamicin was reintroduced to the market in 2017, with new dosing requirements and schedule, and it is now being combined with standard regimens for favorable-risk AML. (ascopost.com)
Both regimens achieved high rates of remission as induction therapy in patients with favorable-risk AML, but FLAG-GO was associated with an improved relapse-free survival rate and achieved a greater reduction in minimal residual disease, using fusion transcription ratio as a surrogate measure. (ascopost.com)
Patients with core-binding factor AML are considered favorable risk and highly responsive to high-dose cytarabine, such as used in FLAG-based regimens. (ascopost.com)
Venetoclax combination with standard regimens in follicular lymphoma, multiple myeloma and aggressive B cell neoplasms has shown some promise, but further studies are required to optimize dose and scheduling to mitigate increased myelosuppression and infection risk, and to find validated biomarkers of venetoclax sensitivity. (biomedcentral.com)

To report experience with three main high-dose methotrexate (HDMTX)-based protocols for PCNSL treatment at one medical center. (ima.org.il)
Early studies with induction including 6-mercatopurine (6-MP) alone or in combination with steroids, methyl-glyoxal guanyl hydrazine and/or methotrexate led to poor results. (nature.com)
I. To determine if the administration of post-Induction age-adjusted intrathecal triple therapy (ITT) on a Modified Berlin-Frankfurt-Munster (MBFM) interim maintenance high-dose methotrexate (IMHDM) backbone will improve 5-year disease-free survival (DFS) of children with high-risk (HR) B-acute lymphoblastic leukemia (ALL) compared to age-adjusted intrathecal (IT) methotrexate (MTX). (uchicagomedicine.org)

It consists of monoclonal antibody rituximab and high-dose antimetabolite cytarabine. (wikipedia.org)
High-dose Ara-C (HDAC) without rituximab also has several other uses in oncohematology. (wikipedia.org)

There are 2 forms of treatment for AML: induction therapy for complete remission (CR) and consolidation therapy to maintain CR. (pharmacytimes.com)
After induction therapy, a patient is given consolidation therapy done with high-dose cytarabine. (pharmacytimes.com)
HDAC also can be used as the primary induction therapy in AML, with higher than in 7+3 success (remission) rate, but it is more toxic and causes more treatment-related complications and treatment-related mortality than 7+3 when used as primary induction therapy. (wikipedia.org)
We report a survival case of invasive splenic mucormycosis involving the liver caused by Rhizopus microsporus in a patient during consolidation therapy for acute monocytic leukemia (AML-M 5 ). (frontiersin.org)
Improved induction therapy could yield more CRs or CRs of longer duration. (ashpublications.org)
To determine in a randomized study design whether the incidence and/or severity of acute vincristine-induced peripheral neuropathy can be reduced by decreasing the dosage of vincristine in patients with the high-risk CEP72 TT genotype or by shortening the duration of vincristine therapy in standard/high-risk patients with the CEP72 CC or CT genotype. (centerwatch.com)
To determine the tolerability of combination therapy with ruxolitinib and Early Intensification therapy in patients with activation of JAK-STAT signaling that can be inhibited by ruxolitinib and Day 15 or Day 22 MRD ≥5%, Day 42 MRD ≥1%, or LLy patients without complete response at the End of Induction and all patients with early T cell precursor leukemia. (centerwatch.com)
We evaluated the use of cytarabine plus either standard-dose or high-dose daunorubicin as induction therapy, followed by intensive consolidation therapy, in inducing complete remission to improve overall survival. (qxmd.com)
In young adults with AML, intensifying induction therapy with a high daily dose of daunorubicin improved the rate of complete remission and the duration of overall survival, as compared with the standard dose. (qxmd.com)
33 patients received a HDMTX backbone induction therapy, 21 (58.3%) received consolidation treatment in addition. (ima.org.il)
All patients (N = 101) received 2 cycles of ATO therapy during consolidation 1. (targetedonc.com)
At the start of post-consolidation therapy, there was no re-randomization. (cancerfax.com)
The sQPCR assay was used to assess fusion transcripts during consolidation therapy. (ascopost.com)
A prospective study demonstrated that low dose decitabine + venetoclax is as safe and efficacious as maintenance therapy following allo-HSCT in patients with high-risk AML/MDS. (devbrandcast.com)
Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. (devbrandcast.com)
Sabatolimab, an immunotherapeutic therapy targeting TIM-3 on immune and myeloid cells, was well-tolerated and led to durable clinical responses when combined with hypomethylating agents in patients with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and newly diagnosed AML. (devbrandcast.com)
Patients who fail induction treatment or relapse have essentially two choices of therapy. (radiationoncologyassociates.co)
Patients with relapsed ALL who choose to have more aggressive therapy should be treated on protocols which are evaluating novel therapies as the current treatments for this phase of ALL do not result in high long-term survival rates. (radiationoncologyassociates.co)
some patients will need ongoing maintenance therapy depending on how much consolidation treatment they have received, as well as if they had a stem cell transplant. (oncolink.org)
Perform electrocardiograms (ECGs) to monitor the QTc at baseline, weekly during induction and consolidation therapy, weekly for at least the first month of maintenance, and periodically thereafter. (dsiaccesscentral.com)
TPMT polymorphisms and minimal residual disease after 6-mercaptopurine post-remission consolidation therapy of childhood acute lymphoblastic leukaemia. (cancercentrum.se)

In the high-dose regimen, cytarabine is given at 3 g/ m2 every 12 hours for 3 days of each cycle. (pharmacytimes.com)
Patients receive 3 to 4 cycles of a given consolidation regimen. (pharmacytimes.com)
HDAC is also used as a consolidation regimen in acute myeloid leukemia after initial 7+3 induction. (wikipedia.org)
Early efforts used the well-established conditioning regimen of carmustine, etoposide, cytarabine and melphalan (BEAM), and more recent trials have used thiotepa-based conditioning, either alone or in comparison with BEAM, owing to thiotepa's superior CNS penetration, because components of the BEAM regimen do not effectively cross the blood-brain barrier. (jamanetwork.com)
Venetoclax with azacitidine (ven/aza) has emerged as a promising regimen for AML, with a high percentage of clinical remissions in newly diagnosed patients. (devbrandcast.com)
A combination regimen consisting of azacitidine with venetoclax and magrolimab showed clinical activity in older and high-risk patients with newly diagnosed AML. (devbrandcast.com)
To determine, in a randomized fashion, if the cyclophosphamide + etoposide containing regimen (Experimental Arm 1) will improve the 4-year DFS of children, adolescents, and young adults with very high-risk (VHR) B-ALL compared to a modified MBFM-IMHDM regimen that contains a second IM (Control Arm). (uchicagomedicine.org)

Challenge: A Phase III Study Of The Impact Of A Physical Activity Program On Disease-Free Survival In Patients With High Risk Stage II Or Stage III Colon Cancer: A Randomised Controlled Trial CHALLENGE aims to determine whether a supervised physical activity (PA) programme in patients with high risk Stage II or Stage III colon cancer will improve 3- year disease-free survival (DFS) in comparison to standard care. (cardiff.ac.uk)
A higher rate of complete remission was observed in the high-dose daunorubicin group (70.6%) relative to the conventional dose (57.3%) as well as an improved overall survival (median, 23.7 mo) compared with the group administered the conventional dose (15.7 mo). (medscape.com)
However, 2 studies demonstrated improved disease-free survival rates in younger patients who received high-dose cytarabine during induction. (medscape.com)
It accounts for approximately 25% of all adult leukemia's worldwide, with the highest incidence rates & also the lowest survival rates of all adult leukemia. (gubbanews.com)

The Food and Drug Administration approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), with prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved test. (cancerfax.com)
South San Francisco, CA - Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the presentation of results from an ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). (baycitycapital.com)
To date, the combination of vosaroxin and decitabine has been found to be effective and well tolerated in older patients with AML and high-risk MDS. (baycitycapital.com)
CONCLUSION: A short course of Elo-KRd induction followed by Elo-lenalidomide maintenance demonstrated activity in predominantly lenalidomide-refractory and / or high-risk MM. The results with this well-tolerated combination are comparable to other contemporary approved triplet combinations. (bvsalud.org)
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study. (devbrandcast.com)
The recommended initial intensive treatment for AML outside a clinical study is DA, i.e., daunorubicin, i.v. infusion 60 mg/m 2 /8h daily for 3 days in combination with cytarabine, i.v. infusion 1 g/m 2 /2h b.i.d daily for 5 days. (cancercentrum.se)

Mucormycosis is a rare opportunistic fungal infection associated with high mortality that typically occurs in immunocompromised patients. (frontiersin.org)
Thirty-day mortality (2 2 .5% vs. 13.8%) and 1-year mortality (25% vs. 15%) were higher among patients with COVID-19 and CIED. (ima.org.il)
Patients with COVID-19 and CIED had a significantly higher prevalence of co-morbidities that were associated with increased mortality. (ima.org.il)
10% Induction mortality. (uchicagomedicine.org)

Standard-risk patients received 3 prophylactic treatments of intrathecal cytarabine and high-risk patients received 4. (targetedonc.com)

In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype. (unipv.it)
Patients were eligible if they had AML or high-risk MDS (defined as having = 10% blasts in the bone marrow), were 60 years of age or older, and had adequate performance status (ECOG = 2) and organ function. (baycitycapital.com)

For example, HDAC, alone or alternating with HD-MTX, is often used for primary CNS lymphoma and for treating CNS involvement in any lymphomas, and also for so-called "CNS prophylaxis" (prophylactic use in those forms of lymphoma which show no signs of CNS involvement at diagnosis but have high chance of CNS relapse or recurrence). (wikipedia.org)

This is particularly apparent from the entree of high-throughput diagnostic technologies and the identification of prognostic and therapeutic targets, the introduction of therapies in genetically defined subgroups of AML, as well as the influx of investigational approaches and novel drugs into the pipeline of clinical trials that target pathogenetic mechanisms of the disease. (ashpublications.org)

Continuous efforts are being made to improve the efficacy of remission induction treatment. (ashpublications.org)

Historically, physicians have included high doses of anthracyclines in the treatment of pediatric APL. (targetedonc.com)
However, anthracyclines are associated with an increased risk for cardiac toxicity, and the risk grows with higher cumulative doses (≥300 mg/m 2 ) and younger age at exposure. (targetedonc.com)

OBJECTIVES: I. Assess the feasibility and outcome of intensified induction/consolidation followed by intensified re-induction/re-intensification in infants less than 1 year of age with newly diagnosed acute lymphocytic leukemia (ALL). (knowcancer.com)
Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. (devbrandcast.com)

Patients and those who have favorable-risk AML will get 3 to 4 cycles of high-dose cytarabine. (pharmacytimes.com)
Consolidation included 2 cycles of ATRA and ATO. (targetedonc.com)
Vosaroxin dose was reduced to 70 mg/m2 in consolidation cycles, which were repeated in approximately four to five week intervals for a total of up to seven cycles. (baycitycapital.com)
METHODS: Enrolled patients received Elo-KRd induction for 4 cycles, and Elo-lenalidomide maintenance until progression. (bvsalud.org)

In this study, they do this to find a suitable dose for venetoclax and to check for potential medical problems from the treatment. (uci.edu)
In Phase 1, different small groups of people will take venetoclax tablets containing lower to higher doses in the combined treatment. (uci.edu)
This is done to find a suitable dose of venetoclax to use in phase 2 of the study. (uci.edu)
At the recommended phase II dosing, venetoclax was administered on days 1-14 during induction and days 1-7 in consolidation. (bjh.be)
Elderly patients with secondary AML, high-risk genetics or significant co-morbidites should rather receive treatment with hypomethylating agents such as azacitidine, with or without venetoclax. (cancercentrum.se)

The objective of this study is to assess the safety and tolerability, including the maximum tolerated dose, of ASP2215 in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML). (mayo.edu)
Dr. Löwenberg describes upcoming possibilities for predicting prognosis in defined subsets by molecular markers and reviews experimental strategies to improve remission induction and postinduction treatment. (ashpublications.org)
The treatment usually involves a remission induction phase aimed at establishing a complete remission and a postinduction phase aimed at eradicating "occult" residual disease. (ashpublications.org)
They will be treated with the suitable doses of the combined treatment worked out from Phase 1. (uci.edu)
In a similar study in patients 60 years of age or older by Lowenberg et al, 813 patients received either conventional-dose treatment (daunorubicin 45 mg/m 2 /d for 3 d) or escalated-dose treatment (daunorubicin 90 mg/m 2 /d for 3 d), both administered over 3 hours on days 1, 2, and 3. (medscape.com)
Chronic leukemia showed higher treatment duration. (sld.cu)
ldquo;Furthermore, the 3-year EFS [of] 83% and OS [of] 86% for the high-risk group compares favorably to reported outcomes in other pediatric APL trials, including the 3-year EFS of 74% in AIDA 0493 and 5-year OS of 83% in Spanish Cooperative Group for Hematological Malignancies Treatment, Spanish Society of Hematology (PETHEMA) LPA96 and LPA99 trials. (targetedonc.com)
The treatment of older patients with AML or high-risk MDS presents particular challenges, including many patients not tolerating or responding to existing therapies," said Farhad Ravandi, M.D., Professor of Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, and a study investigator. (baycitycapital.com)
Do not initiate treatment with VANFLYTA or escalate the VANFLYTA dose if the QT interval corrected by Fridericia's formula (QTcF) is greater than 450 ms. (dsiaccesscentral.com)

One hundred twenty-three patients were eligible for high-dose cytarabine-based consolidation administered in two to three courses. (elsevierpure.com)
Only R/R-AML patients were eligible for the phase IB (dose escalation) portion of the trial. (bjh.be)

The high number of complete remissions with good tolerability are highly encouraging and make this trial a designated priority for our center. (baycitycapital.com)

The standard dosage for cytarabine of 200 mg/m2 /day. (pharmacytimes.com)
In this phase 3 randomized trial, we assigned 657 patients between the ages of 17 and 60 years who had untreated AML to receive three once-daily doses of daunorubicin at either the standard dose (45 mg per square meter of body-surface area) or a high dose (90 mg per square meter), combined with seven daily doses of cytarabine (100 mg per square meter) by continuous intravenous infusion. (qxmd.com)
Investigators separated patients into standard-risk (n= 66) or high-risk (n = 35) groups. (targetedonc.com)
OS was 98% for standard-risk patients versus 86% for high risk ( P = .003). (targetedonc.com)

A difference in CR and PFS favored a more aggressive protocol, but the toxicity of the multiagent combinations was significantly higher. (ima.org.il)
Dose adjustments and dose delays of one or both agents were allowed based on toxicity. (baycitycapital.com)
I. To determine the toxicity and tolerability of post-Induction age-adjusted ITT compared to age-adjusted IT MTX in children with HR B-ALL. (uchicagomedicine.org)

Dr. Ravandi is also a principal investigator of the Phase 3 VALOR trial, the company's randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin plus cytarabine in patients with first relapsed or refractory AML. (baycitycapital.com)
RESULTS: Of 15 patients enrolled, 10 (67%) had high-risk features (del17p, t[4;14], t[14;16], 1q gain/amplification, plasma cell leukemia, extramedullary MM, or functional high risk), 12 (80%) were lenalidomide-refractory, and 5 (33.3%) bortezomib-refractory. (bvsalud.org)

[ 36 ] In both cases, patients received cytarabine 200 mg/m 2 /d as a continuous infusion for 7 days. (medscape.com)

moreover, all responders proved eligible for intensive consolidation. (unipv.it)
Adult patients with ND-AML, high-risk myelodysplastic syndrome or R/R-AML were eligible. (bjh.be)

Historically, APL has been characterized by a rapidly fatal course with a high incidence of early hemorrhagic death. (nature.com)
APL has been associated with a high incidence of early hemorrhagic death. (nature.com)

Our results show an improved LFS for younger patients treated with high-dose cytarabine-based consolidation. (elsevierpure.com)
In a study by Fernandez et al, 657 patients younger than 60 years with untreated AML received either conventional-dose daunorubicin (45 mg/m 2 /d for 3 d) or high-dose daunorubicin (90 mg/m 2 /d for 3 d). (medscape.com)
The prognosis in younger was better than in older patients, with higher rates of CR, PFS, and OS, although not statistically significant. (ima.org.il)

ATRA was administered at a divided daily dose of 25 mg/m 2 on induction days 1 to 30, and days 1 to 14 of each consolidation course and each maintenance cycle. (targetedonc.com)

Instead of anthracyclins, remission induction programs may incorporate mitoxantrone and amsacrine. (ashpublications.org)

VANFLYTA ® (quizartinib) prolongs the QT interval in a dose- and concentration-related manner. (dsiaccesscentral.com)
Reduce the VANFLYTA dose when used concomitantly with strong CYP3A inhibitors, as they may increase quizartinib exposure. (dsiaccesscentral.com)

After the consolidation phase, some continued to receive either midostaurin or placebo for one more year. (incitasecurity.com)

PCNSL is now known to be a form of extranodal, high-grade non-Hodgkin B-cell neoplasm, usually large cell or immunoblastic type. (medscape.com)

Because the affected areas of the CNS differ from patient to patient, clinical signs and symptoms of the disease are variable, and diagnosis requires a high level of suspicion. (medscape.com)

The poster (Poster #7, Hall A-E, Poster Section 38) is titled "Phase I/II study of vosaroxin and decitabine in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). (baycitycapital.com)

According to the initial assignment, patients were randomised (1:1) to receive quizartinib (n = 268) or a placebo (n = 271) with induction, consolidation, and maintenance monotherapy. (cancerfax.com)

The use of high-dose cytarabine outside the setting of a clinical trial is considered controversial. (medscape.com)
The Working Formulation, originally proposed in 1982, classified and grouped lymphomas by morphology and clinical behavior (ie, low, intermediate, or high grade) with 10 subgroups labeled A to J.{Ref 1} In 1994, the Revised European-American Lymphoma (REAL) classification attempted to apply immunophenotypic and genetic features in identifying distinct clinicopathologic NHL entities. (medscape.com)

The purpose of this study is to evaluate the rate of complete MRD response by flow cytometry after 4 weekly doses of daratumumab-hyaluronidase (Day 29) among patients with MRD positive T-ALL in hematologic morphologic complete remission or complete remission with incomplete hematologic recovery. (mayo.edu)
The complete remission rate was 64% in the escalated-dose group compared with 54% in conventional-dose group. (medscape.com)
Hematologic complete response was 81%, but patients could remain on-protocol regardless of response at the end of induction. (targetedonc.com)

The entire cohort received ATRA during induction, each consolidation course, and maintenance. (targetedonc.com)

Elderly patients with intermediate- or high-risk genetics receive a maximum of 2 consolidations. (cancercentrum.se)

Anatomy14

Organisms7

Diseases37

Chemicals and Drugs68

Analytical, Diagnostic and Therapeutic Techniques and Equipment64

Psychiatry and Psychology34

Phenomena and Processes39

Disciplines and Occupations2

Anthropology, Education, Sociology and Social Phenomena1

Technology, Industry, Agriculture1

Information Science3

Health Care22

Chemotherapy27

Idarubicin12

Anthracycline6

Daunorubicin and Cytarabine1

Allogeneic4

Mantle Cell Lym2

Regimens7

Methotrexate3

Rituximab2

Therapy21

Regimen7

Survival4

Combination6

Mortality4

Intrathecal1

Bone marrow2

Prophylactic1

Therapeutic1

Efficacy1

Anthracyclines2

Newly diagnosed2

Cycles4

Venetoclax5

Treatment9

Patients were eligible2

Remissions1

Standard4

Toxicity3

Refractory2

Infusion1

Eligible2

Incidence2

Younger3

Days1

Mitoxantrone1

Vanflyta2

Midostaurin1

PCNSL1

Diagnosis1

Myelodysplastic1

Quizartinib1

Clinical2

Complete3

Entire cohort1

Intermediate1